SCHEMBL15071135

SCHEMBL15071135

CCOC(=O)c1ccc(-c2c(C)nc3ccc(C(=O)N4CCCCC4)cn23)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 1/20 0.58
AKT1 P31749 1/20 0.49
AKT2 P31751 1/20 0.49
ALDH1A1 P00352 4/20 0.47
RAB9A P51151 4/20 0.47
NPC1 O15118 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HPGD P15428 6/20 0.46
HSD17B10 Q99714 3/20 0.46
KDM4E B2RXH2 3/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
KLK7 P49862 1/20 0.46
CASP1 P29466 2/20 0.45
LMNA P02545 1/20 0.45
CASP7 P55210 1/20 0.45
SLC2A1 P11166 1/20 0.44
KCNH2 Q12809 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
PSEN1 P49768 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15071132 0.87 F2RL1 (0.64) F2RL1ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL15071133 0.85 F2RL1 (0.60) F2RL1ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL15071127 0.85 F2RL1 (0.62) F2RL1ALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL15071138 0.85 F2RL1 (0.62) F2RL1AKT1AKT2ALDH1A1RAB9A
SCHEMBL15071130 0.85 F2RL1 (0.62) F2RL1ALDH1A1RAB9ANPC1HPGD
SCHEMBL15071143 0.85 F2RL1 (0.74) F2RL1AKT1AKT2RAB9ANPC1
SCHEMBL15071100 0.85 F2RL1 (0.77) F2RL1AKT1AKT2ALDH1A1RAB9A
SCHEMBL31488 0.81 F2RL1 (0.60) F2RL1ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL31560 0.79 F2RL1 (0.63) F2RL1ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL15071136 0.78 F2RL1 (0.62) F2RL1ALDH1A1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME F2RL1, F2R, FPR2 F2RL1 1/4885AKT1 669/4885AKT2 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.